First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients

MJ Zacherl, FJ Gildehaus, L Mittlmeier… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Treatment of advanced metastatic castration-resistant prostate cancer after failure of
approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA) …

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

F Khreish, N Ebert, M Ries, S Maus, F Rosar… - European journal of …, 2020 - Springer
Purpose Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive
metastatic castration-resistant prostate cancer (mCRPC) never respond or develop …

[HTML][HTML] Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha …

MJ van der Doelen, N Mehra, IM van Oort… - … Oncology: Seminars and …, 2021 - Elsevier
Introduction Targeted alpha-radiation therapy (TAT) with 225 Ac-labeled prostate-specific
membrane antigen (PSMA) ligands is a promising novel treatment option for metastatic …

[HTML][HTML] Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer

A Juzeniene, VY Stenberg, ØS Bruland, RH Larsen - Cancers, 2021 - mdpi.com
Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer

M Sathekge, O Knoesen, M Meckel… - European Journal of …, 2017 - Springer
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA
holds great promise as a safe treatment option in patients with metastasized castration …

[HTML][HTML] The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body …

J Maffey-Steffan, L Scarpa, A Svirydenka… - European journal of …, 2020 - Springer
Introduction A new therapeutic option for metastatic castration–resistant prostate cancer
(mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy …

Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA

B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti… - European urology, 2021 - Elsevier
Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …

mCRPC patients receiving 225Ac-PSMA-617 therapy in the post–androgen deprivation therapy setting: response to treatment and survival analysis

M Sathekge, F Bruchertseifer, M Vorster… - Journal of Nuclear …, 2022 - Soc Nuclear Med
225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is
overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in …

225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer

C Kratochwil, F Bruchertseifer, FL Giesel… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …

Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor …

C Kratochwil, F Bruchertseifer, H Rathke… - Journal of Nuclear …, 2018 - Soc Nuclear Med
The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …